5-(4-Phenoxybutoxy)psoralen - CAS 870653-45-5
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
5-(4-Phenoxybutoxy)psoralen
Catalog Number:
870653-45-5
Synonyms:
PAP-1;7H-Furo[3,2-g][1]benzopyran-7-one, 4-(4-phenoxybutoxy)-;4-(4-Phenoxybutoxy)-7H-furo[3,2-g][1]benzopyran-7-one;2-g][1]benzopyran-7-one;4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one
CAS Number:
870653-45-5
Description:
5-(4-Phenoxybutoxy)psoralen is selective inhibitor of Kv1.3, voltage-gated K+ channel. It potently inhibits human T effector memory cell proliferation and delayed hypersensitivity. It has 23-fold selectivity for Kv1.3 over Kv1.5. It is used in treatment of multiple sclerosis. It was developed by Airmid company and is in Cilinic phase 1.
Molecular Weight:
350.36
Molecular Formula:
C21H18O5
Quantity:
Milligrams-Grams
Quality Standard:
In-house standard
COA:
Inquire
MSDS:
Inquire
Canonical SMILES:
C1=CC=C(C=C1)OCCCCOC2=C3C=CC(=O)OC3=CC4=C2C=CO4
InChI:
InChI=1S/C21H18O5/c22-20-9-8-16-19(26-20)14-18-17(10-13-24-18)21(16)25-12-5-4-11-23-15-6-2-1-3-7-15/h1-3,6-10,13-14H,4-5,11-12H2
InChIKey:
KINMYBBFQRSVLL-UHFFFAOYSA-N
Targets:
Potassium voltage-gated channel(KCNA3)
Current Developer:
5-(4-Phenoxybutoxy)psoralen was developed by Airmid company and is in Cilinic phase 1.
Chemical Structure
CAS 870653-45-5 5-(4-Phenoxybutoxy)psoralen

Related Potassium voltage-gated channel(KCNA3) Products


CAS 870653-45-5 5-(4-Phenoxybutoxy)psoralen

5-(4-Phenoxybutoxy)psoralen
(CAS: 870653-45-5)

5-(4-Phenoxybutoxy)psoralen is selective inhibitor of Kv1.3, voltage-gated K+ channel. It potently inhibits human T effector memory cell proliferation and delay...

Reference Reading


1.Identification of phase-I metabolites and chronic toxicity study of the Kv1.3 blocker PAP-1 (5-(4-phenoxybutoxy)psoralen) in the rat.
Hao B1, Chen ZW, Zhou XJ, Zimin PI, Miljanich GP, Wulff H, Wang YX. Xenobiotica. 2011 Mar;41(3):198-211. doi: 10.3109/00498254.2010.532886. Epub 2010 Nov 11.
1. PAP-1 (5-(4-phenoxybutoxy)psoralen), a potent small-molecule blocker of the voltage-gated potassium Kv1.3 channel, is currently in preclinical development for psoriasis. This study was undertaken to identify the major phase I metabolites of PAP-1 in Sprague-Dawley (SD) rats. 2. Five phase I metabolites, that is 5-(oxybutyric-acid)psoralen (M1), 5-[4-(4-hydroxybutoxy)]psoralen (M2), 5-[4-(4-hydroxyphenoxy)butoxy]psoralen (M3), 5-[4-(3-hydroxyphenoxy)butoxy]psoralen (M4), and 8-hydroxyl-5-(4-phenoxybutoxy)psoralen (M5), were isolated from the bile of rats and identified by mass spectrometry and NMR spectroscopy. The last four metabolites are new compounds. 3. Incubation of PAP-1 with SD rat liver microsomes rendered the same five major metabolites in a nicotinamide adenine dinucleotide phosphate (NADPH)-dependent manner suggesting that cytochrome P450 (CYP) enzymes are involved in PAP-1 metabolism. Inhibitors of rat CYP1A1/2 (alpha-naphthoflavone) and CYP3A (ketoconazole) but not CYP2D6 (quinidine), CYP2E (diethyldithiocarbamate), or CYP2C9 (sulphaphenazole) blocked the metabolism of PAP-1 in rat microsomes.
2.HIV-1 Tat protein increases microglial outward K(+) current and resultant neurotoxic activity.
Liu J1, Xu P, Collins C, Liu H, Zhang J, Keblesh JP, Xiong H. PLoS One. 2013 May 30;8(5):e64904. doi: 10.1371/journal.pone.0064904. Print 2013.
Microglia plays a crucial role in the pathogenesis of HIV-1-associated neurocognitive disorders. Increasing evidence indicates the voltage-gated potassium (Kv) channels are involved in the regulation of microglia function, prompting us to hypothesize Kv channels may also be involved in microglia-mediated neurotoxic activity in HIV-1-infected brain. To test this hypothesis, we investigated the involvement of Kv channels in the response of microglia to HIV-1 Tat protein. Treatment of rat microglia with HIV-1 Tat protein (200 ng/ml) resulted in pro-inflammatory microglial activation, as indicated by increases in TNF-α, IL-1β, reactive oxygen species, and nitric oxide, which were accompanied by enhanced outward K(+) current and Kv1.3 channel expression. Suppression of microglial Kv1.3 channel activity, either with Kv1.3 channel blockers Margatoxin, 5-(4-Phenoxybutoxy)psoralen, or broad-spectrum K(+) channel blocker 4-Aminopyridine, or by knockdown of Kv1.
3.Pharmacological inhibition of Kv1.3 fails to modulate insulin sensitivity in diabetic mice or human insulin-sensitive tissues.
Straub SV1, Perez SM, Tan B, Coughlan KA, Trebino CE, Cosgrove P, Buxton JM, Kreeger JM, Jackson VM. Am J Physiol Endocrinol Metab. 2011 Aug;301(2):E380-90. doi: 10.1152/ajpendo.00076.2011. Epub 2011 May 17.
Genetic ablation of the voltage-gated potassium channel Kv1.3 improves insulin sensitivity and increases metabolic rate in mice. Inhibition of Kv1.3 in mouse adipose and skeletal muscle is reported to increase glucose uptake through increased GLUT4 translocation. Since Kv1.3 represents a novel target for the treatment of diabetes, the present study investigated whether Kv1.3 is functionally expressed in human adipose and skeletal muscle and whether specific pharmacological inhibition of the channel is capable of modulating insulin sensitivity in diabetic mouse models. Voltage-gated K(+) channel currents in human skeletal muscle cells (SkMC) were insensitive to block by the specific Kv1.3 blockers 5-(4-phenoxybutoxy)psoralen (PAP-1) and margatoxin (MgTX). Glucose uptake into SkMC and mouse 3T3-L1 adipocytes was also unaffected by treatment with PAP-1 or MgTX. Kv1.3 protein expression was not observed in human adipose or skeletal muscle from normal and type 2 diabetic donors.
4.Potassium channel block by a tripartite complex of two cationophilic ligands and a potassium ion.
Zimin PI1, Garic B, Bodendiek SB, Mahieux C, Wulff H, Zhorov BS. Mol Pharmacol. 2010 Oct;78(4):588-99. doi: 10.1124/mol.110.064014. Epub 2010 Jul 2.
Voltage-gated potassium channels (Kv) are targets for drugs of large chemical diversity. Although hydrophobic cations block Kv channels with Hill coefficients of 1, uncharged electron-rich (cationophilic) molecules often display Hill coefficients of 2. The mechanism of the latter block is unknown. Using a combination of computational and experimental approaches, we mapped the receptor for the immunosuppressant PAP-1 (5-(4-phenoxybutoxy)psoralen), a high-affinity blocker of Kv1.3 channels in lymphocytes. Ligand-docking using Monte Carlo minimizations suggested a model in which two cationophilic PAP-1 molecules coordinate a K(+) ion in the pore with their coumarin moieties, whereas the hydrophobic phenoxyalkoxy side chains extend into the intrasubunit interfaces between helices S5 and S6. We tested the model by generating 58 point mutants involving residues in and around the predicted receptor and then determined their biophysical properties and sensitivity to PAP-1 by whole-cell patch-clamp.